{"id":134058,"date":"2022-01-14T17:25:00","date_gmt":"2022-01-15T01:25:00","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2022\/01\/pfizer-seeks-approval-for-oral-covid-19-pill-in-japan"},"modified":"2022-01-14T17:25:00","modified_gmt":"2022-01-15T01:25:00","slug":"pfizer-seeks-approval-for-oral-covid-19-pill-in-japan","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2022\/01\/pfizer-seeks-approval-for-oral-covid-19-pill-in-japan","title":{"rendered":"Pfizer seeks approval for oral COVID-19 pill in Japan"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/pfizer-seeks-approval-for-oral-covid-19-pill-in-japan.jpg\"><\/a><\/p>\n<p>Pfizer Japan Inc. said Friday it has applied to the health ministry for approval of its COVID-19 pill which, if granted, would make it the second oral drug for mild coronavirus cases available in the country.<\/p>\n<p>The new drug application for Paxlovid, a combination of the antiviral drugs nirmatrelvir and ritonavir, comes as Japan is battling its sixth surge of COVID-19 cases amid a spread of the omicron variant, with the country already agreeing to procure enough of the drug for 2 million people.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pfizer Japan Inc. said Friday it has applied to the health ministry for approval of its COVID-19 pill which, if granted, would make it the second oral drug for mild coronavirus cases available in the country. The new drug application for Paxlovid, a combination of the antiviral drugs nirmatrelvir and ritonavir, comes as Japan is [\u2026]<\/p>\n","protected":false},"author":513,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,1495],"tags":[],"class_list":["post-134058","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-health"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/134058","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/513"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=134058"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/134058\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=134058"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=134058"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=134058"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}